EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Rademikibart ( CBP ‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα : Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis

Junying Wang, Jeffery White, Kenneth J Sansone, Lynda Spelman iD, Rodney Sinclair, Xin Yang, Wubin Pan, Zheng Wei

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13656 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Junying Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Suzhou Connect Biopharmaceuticals, Taicang, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human IgG4 kappa monoclonal antibody, blocks IL‐4Rα‐mediated signal transduction. We performed two phase I, randomized, double‐blind, placebo‐controlled trials. In a single‐ascending dose trial, 40 healthy adults were randomized 3:1 to rademikibart (75–600 mg s.c., 300 mg i.v.) or placebo, with 12 weeks of follow‐up. In the multiple‐ascending dose trial, 31 adults with moderate‐to‐severe AD were randomized 4:1 to once weekly rademikibart (75–300 mg s.c.) or placebo for 4 weeks, plus 7 weeks of follow‐up. Most treatment‐emergent adverse events (TEAEs) were mild; none were serious. Two s.c. injection site reactions and one TEAE of conjunctivitis were reported, all were mild. Rapid and sustained improvements were observed in AD severity and in quality of life (QoL), without plateauing. At week 4, efficacy scores improved by a maximum of −74.4% (Eczema Area and Severity Index), −62.7% (body surface area), −52.8% (Pruritus Numerical Rating Scale [PNRS] severity), −54.4% (PNRS frequency), and − 69.9% (Dermatology Life Quality Index). Thymus activation regulated chemokine inflammatory biomarker concentrations decreased in both trials (−55.4% in the pooled rademikibart arms vs. +18.0% with placebo, at week 5, in patients with AD). Exposure to rademikibart increased in a greater than dose‐proportional manner, suggesting nonlinear clearance. In summary, rademikibart was well‐tolerated and associated with rapid and sustained improvements in eczematous lesions, pruritus, QoL, and inflammatory biomarker concentrations during 4 weeks of treatment. Efficacy responses did not plateau and were generally dose dependent. These promising findings support further development of rademikibart in patients with AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalDermatitis, AtopicHumansAntibodies, Monoclonal, HumanizedBiomarkersDouble-Blind MethodPruritusQuality of LifeSeverity of Illness IndexTreatment OutcomeInterleukin-4 Receptor alpha Subunit

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersIL4R protein, humanInterleukin-4 Receptor alpha Subunit

Autor:innen und Institutionen

  • Suzhou Connect Biopharmaceuticals, Taicang, China.
  • Connect Biopharma, San Diego, California, USA.
  • Veracity Clinical Research Pty Ltd., Woolloongabba, Queensland, Australia.
  • Sinclair Dermatology, East Melbourne, Victoria, Australia.

ORCID-Profile: Lynda Spelman

Zitieren

APA

Wang, J., White, J., Sansone, K. J., Spelman, L., Sinclair, R., Yang, X., Pan, W., & Wei, Z. (2023). Rademikibart ( CBP ‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα : Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clinical and Translational Science. https://doi.org/10.1111/cts.13656

Vancouver

Wang J, White J, Sansone KJ, Spelman L, Sinclair R, Yang X, et al. Rademikibart ( CBP ‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα : Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clinical and Translational Science. 2023. doi:10.1111/cts.13656

BibTeX
@article{Wang2023,
  author = {Wang, Junying and White, Jeffery and Sansone, Kenneth J and Spelman, Lynda and Sinclair, Rodney and Yang, Xin and Pan, Wubin and Wei, Zheng},
  title = {Rademikibart ( CBP ‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα : Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13656}
}
Kostenlos starten →